Vor Biopharma Inc. Operating Expenses
Vor Biopharma Inc. (VOR) reported Operating Expenses of $47.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Vor Biopharma Inc. operating expenses for the quarter ending 2026-06-30 was $47.85M, a 82.55% decline year-over-year.
- Vor Biopharma Inc. operating expenses for the quarter ending 2026-03-31 was $35.16M, a 5.61% increase year-over-year.
- Vor Biopharma Inc. operating expenses for the quarter ending 2025-12-31 was $35.96M, a 14.85% increase year-over-year.
- Vor Biopharma Inc. operating expenses for the quarter ending 2025-09-30 was $28.11M, a 1.42% decline year-over-year.
- Vor Biopharma Inc. operating expenses for fiscal 2025 was $371.64M, a 206.67% increase from fiscal 2024.
- Vor Biopharma Inc. operating expenses for fiscal 2024 was $121.19M, a 3.85% decline from fiscal 2023.
- Vor Biopharma Inc. operating expenses for fiscal 2023 was $126.04M, a 34.92% increase from fiscal 2022.
- Vor Biopharma Inc. operating expenses for fiscal 2022 was $93.42M, a 35.35% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.85M 10-Q · filed 2026-08-11 | $83.01M 10-Q · filed 2026-08-11 | $118.97M derived: sum of 3 quarters · filed 2026-08-11 | $147.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $35.16M 10-Q · filed 2026-05-13 | $71.12M derived: sum of 2 quarters · filed 2026-05-13 | $99.23M derived: sum of 3 quarters · filed 2026-05-13 | $373.51M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $35.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $64.07M derived: sum of 2 quarters · filed 2026-03-30 | $338.35M derived: sum of 3 quarters · filed 2026-08-11 | $371.64M 10-K · filed 2026-03-30 |
| 2025-09-30 | $28.11M 10-Q · filed 2025-11-13 | $302.39M derived: sum of 2 quarters · filed 2026-08-11 | $335.68M 10-Q · filed 2025-11-13 | $366.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $274.28M 10-Q · filed 2026-08-11 | $307.57M 10-Q · filed 2026-08-11 | $338.89M derived: sum of 3 quarters · filed 2026-08-11 | $367.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $33.29M 10-Q · filed 2026-05-13 | $64.60M derived: sum of 2 quarters · filed 2026-05-13 | $93.11M derived: sum of 3 quarters · filed 2026-05-13 | $122.15M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $31.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $59.82M derived: sum of 2 quarters · filed 2026-03-30 | $88.86M derived: sum of 3 quarters · filed 2026-03-30 | $121.19M 10-K · filed 2026-03-30 |
| 2024-09-30 | $28.51M 10-Q · filed 2025-11-13 | $57.55M derived: sum of 2 quarters · filed 2025-11-13 | $89.87M 10-Q · filed 2025-11-13 | $118.00M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $29.04M 10-Q · filed 2025-08-12 | $61.36M 10-Q · filed 2025-08-12 | $89.48M derived: sum of 3 quarters · filed 2025-08-12 | $124.80M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $32.33M 10-Q · filed 2025-05-14 | $60.45M derived: sum of 2 quarters · filed 2025-05-14 | $95.77M derived: sum of 3 quarters · filed 2025-05-14 | $127.94M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $28.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $63.44M derived: sum of 2 quarters · filed 2025-03-20 | $95.61M derived: sum of 3 quarters · filed 2025-03-20 | $126.04M 10-K · filed 2025-03-20 |
| 2023-09-30 | $35.32M 10-Q · filed 2024-11-07 | $67.49M derived: sum of 2 quarters · filed 2024-11-07 | $97.91M 10-Q · filed 2024-11-07 | $122.64M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $32.17M 10-Q · filed 2024-08-08 | $62.60M 10-Q · filed 2024-08-08 | $87.32M derived: sum of 3 quarters · filed 2024-08-08 | $111.42M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $30.42M 10-Q · filed 2024-05-09 | $55.15M derived: sum of 2 quarters · filed 2024-05-09 | $79.25M derived: sum of 3 quarters · filed 2024-05-09 | $101.04M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $24.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $48.83M derived: sum of 2 quarters · filed 2024-03-20 | $70.62M derived: sum of 3 quarters · filed 2024-03-20 | $93.42M 10-K · filed 2024-03-20 |
| 2022-09-30 | $24.10M 10-Q · filed 2023-11-07 | $45.89M derived: sum of 2 quarters · filed 2023-11-07 | $68.69M 10-Q · filed 2023-11-07 | $87.00M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $21.79M 10-Q · filed 2023-08-10 | $44.59M 10-Q · filed 2023-08-10 | $62.90M derived: sum of 3 quarters · filed 2023-08-10 | $81.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $22.80M 10-Q · filed 2023-05-11 | $41.11M derived: sum of 2 quarters · filed 2023-05-11 | $59.71M derived: sum of 3 quarters · filed 2023-05-11 | $78.09M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $18.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $36.91M derived: sum of 2 quarters · filed 2023-03-23 | $55.29M derived: sum of 3 quarters · filed 2023-03-23 | $69.02M 10-K · filed 2023-03-23 |
| 2021-09-30 | $18.60M 10-Q · filed 2022-11-10 | $36.98M derived: sum of 2 quarters · filed 2022-11-10 | $50.71M 10-Q · filed 2022-11-10 | $66.38M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $18.38M 10-Q · filed 2022-08-11 | $32.11M 10-Q · filed 2022-08-11 | $47.77M derived: sum of 3 quarters · filed 2022-08-11 | $59.56M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $13.73M 10-Q · filed 2022-05-12 | $29.39M derived: sum of 2 quarters · filed 2022-05-12 | $41.18M derived: sum of 3 quarters · filed 2022-05-12 | $49.22M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $27.45M derived: sum of 2 quarters · filed 2022-03-14 | $35.49M derived: sum of 3 quarters · filed 2022-03-14 | $43.37M 10-K · filed 2022-03-14 |
| 2020-09-30 | $11.79M 10-Q · filed 2021-11-10 | $19.82M derived: sum of 2 quarters · filed 2021-11-10 | $27.70M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $8.04M 10-Q · filed 2021-08-09 | $15.92M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $7.88M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |